The role of platelet glucose-6-phosphate dehydrogenase (G-6-PD) in mediating the effects of human platelets on oxidant-induced edema in the isolated perfused rabbit lung was investigated using dehydroepiandrosterone, a specific steroidal inhibitor of G-6-PD. Xanthine oxidase (0.003 and 0.012 U/ml) caused lung edema that was attenuated by coinfusion of washed human platelets. Platelets that were incubated with DEA to inhibit G-6-PD activity augmented xanthine oxidase-induced lung edema and pulmonary hypertension at both doses of xanthine oxidase. Infusion of papaverine to maintain stable pulmonary artery (PA) pressures, incubation of G-6-PD-inhibited platelets with acetylsalicylate, or infusion of a thromboxane-prostaglandin endoperoxide receptor site antagonist, SQ 29548, into the lung perfusate prevented augmentation of lung edema and the PA pressor response by G-6-PD-inhibited platelets. It was concluded that antioxidantintact platelets attenuate oxidant-induced lung edema by preventing increased membrane permeability, and that G-6-PD-inhibited platelets augment lung edema through hydrostatic mechanisms mediated by release of platelet cyclooxygenase products. 
body complexes cause vascular injury and inflammation in rabbits (1 1), and thrombocytopenia attenuates vascular injury after complement activation by cobra venom factor ( 12) . Because activated platelets release potent vasoconstrictors, such as 5-hydroxytryptamine, histamine, adenine nucleotides, prostaglandin endoperoxides, and TXA2 (13, 14) , platelets may further indirectly enhance membrane permeability edema in conditions such as edematous lung injury by causing pulmonary hypertension and increased intracapillary hydrostatic pressure (15) .
Whether platelets are beneficial or deleterious to membrane permeability in the pulmonary microvasculature is a particularly important question. Biopsy and autopsy specimens from patients with the adult respiratory distress syndrome (ARDS)I demonstrate that platelets sequester in regions of lung injury (16, 17) . Elucidation of the role of platelets in the pathogenesis ofARDS, however, has been lacking (18) . We have previously demonstrated that human platelets can attenuate edema in the isolated perfused rabbit lung infused with xanthine oxidase (an enzyme that simulates neutrophil release of continuous low levels of several toxic oxygen metabolites), and that the protective effect is mediated through the platelet glutathione redox cycle (19) . These findings suggest that platelets can reduce extracellular toxic oxygen metabolites ex vivo and that platelet antioxidant activity may be an important determinant of platelet interactions with vascular endothelium.
3fl-Hydroxy-5-androsten-17-one (dehydroepiandrosterone) is a selective steroidal inhibitor of the hexose monophosphate shunt enzyme glucose-6-phosphate dehydrogenase (G-6-PD) (20, 21) . G-6-PD is an important intracellular antioxidant defense mechanism in that it supplies NADPH for normal functioning ofthe glutathione redox cycle (22, 23) and is stimulated after exposure of platelets to extracellular H202 (24) . We reasoned that normal platelets in the presence of xanthine oxidase may attenuate oxidant-induced edema by reducing toxic oxygen metabolites, and that G-6-PD-inhibited platelets may become oxidant targets themselves, thereby enhancing lung injury through the release of cytotoxic or vasoconstrictive substances. In this study, the effect of dehydroepiandrosterone-treated human platelets on xanthine oxidase-induced oxidant lung edema in the isolated perfused rabbit lung was determined.
Methods
Materials. Male and female New Zealand White rabbits weighing between 2 and 2.5 kg were used in all experiments. Animals were housed individually in stainless steel cages in a temperature-controlled environment. [5,6,8,- Preparation of washed human platelets. 100 ml venous blood was drawn using a two-syringe venipucture technique from healthy volunteers who were medication free for 14 d. The syringes contained a citrate solution anticoagulant consisting of 0.085 M trisodium citrate, 0.065 M citric acid, and 2% dextrose in a 1:6 dilution. Platelet-rich plasma (PRP) was prepared by centrifugation of the citrated blood at 275 g for 10 min at 24°C. The PRP was centrifuged at 1,000 g for 15 min at 24°C to form a platelet pellet. The overlying platelet-poor plasma was removed with a plastic transfer pipette, and the pellet was resuspended in 40 ml of Krebs-Henseleit physiologic salt solution that was modified to exclude calcium. The suspension of washed platelets contained 1.20±0.07 X 10'0 cells.
In some experiments, platelets were incubated with agents to inhibit G-6-PD and cyclooxygenase enzyme before infusion into the isolated lung. To inhibit platelet G-6-PD, PRP was incubated with dehydroepiandrosterone (10-6 M) for 30 min at 24°C before preparing washed platelets. Platelet G-6-PD activity after incubation with dehydroepiandrosterone was determined by measuring the generation of NADPH by treated platelets and expressed as nanomoles of NADPH generated per minute by 109 platelets (25) . Glutathione content of platelets incubated with dehydroepiandrosterone was determined using Ellman's reagent and a modification of the glutathione-specific assay of Tietze (26) . The final reaction mixture contained 200 Ml of sonicated washed platelets, 6 mM NADPH, and 6 mM dinitrobenzene in a 0.1 M sodium phosphate buffer (pH 8.0) containing 5 mM EDTA. Glutathione concentration was expressed as nanomoles of glutathione per I09 platelets.
To inhibit both platelet G-6-PD and cyclooxygenase enzyme, PRP was incubated with dehydroepiandrosterone (10-6 M) and acetylsalicylate (100MuM) for 30 min at 24°C before centrifugation and resuspension in Krebs-Henseleit solution.
Preparation of isolated rabbit lungs. After anesthesia with intramuscular xylazine (10 mg/kg; Cutter Laboratory, Shawnee, KS) and intravenous ketamine (25-50 mg/kg; Parke-Davis & Co., Detroit, MI), rabbit heart-lung preparations were removed and isolated. Briefly, the lungs were ventilated through a tracheotomy by a small animal ventilator (model 6700; Harvard Apparatus Co., S. Natick, MA) at 24 breaths/min with a tidal volume of 10-15 ml/kg body weight and 2 cm H20 positive end-expiratory pressure. Animals were ventilated with a mixture of 95% 02 and 5% CO2 that maintained perfusate pH and gas tensions at pH = 7.38-7.46, Pco2 = 34-36 mmHg, and Po2 = 490-520 mmHg. After a midsternal thoracotomy, heparin (500 U) was injected into the right ventricle and the pulmonary artery was cannulated. A second cannula was inserted into the left ventricle (LV) and the heart-lung preparation was suspended in a humidification dome (38°C) from a force-displacement transducer (type 4-327-0010; Grass Instruments, Quincy, MA). The lungs were perfused with a constant flow (100 ml/min) by a peristaltic pump (model 1203; Harvard Apparatus Co.) in a recirculating system containing Krebs-Henseleit physiologic salt solution and 3% BSA. After the lungs were flushed with an initial 500 ml of perfusate to remove residual blood cells and plasma, a recirculating system was established with 300 ml of perfusate. Pulmonary artery (PA) pressure was measured throughout the experiments with a pressure transducer (Bell and Howell Co., Pasadena, CA) and recorded (recorder obtained from Grass Instruments).
Measurement of vascular injury in the isolated lung. Changes in lung weight were continuously measured by the force-displacement transducer and recorded on a polygraph (Grass Instruments). Increases in lung weight were attributed to lung edema. After 60 min of lung perfusion, experiments were terminated and the left lung was isolated and lavaged with 20 ml of isotonic saline. The lung lavage specimens were assayed for albumin concentrations by the bromocresol green method (Technical Bulletin no. 631; Sigma Chemical Co.). Increases in airway albumin content were considered to reflect lung edema formation.
Measurements ofperfusate platelet, erythrocyte, and neutrophil counts. 1-ml perfusate samples were drawn from the LV cannula after the lungs were flushed with 500 ml of perfusate and anticoagulated with EDTA to determine perfusate counts of circulating cellular elements. Perfusate platelet counts were performed (Pacer Plus Counter; Coulter Electronics Inc., Hialeah, FL); platelet counts < 5,000 cells/,ul were confirmed to be background counts by performing hemocytometer platelet counts. Erythrocyte and neutrophil counts in perfusate samples were determined by hemocytometer techniques.
Pe,fusate sample collection and measurement methodsfor iTXB2.
Perfusate samples (3 ml) were drawn from the LV cannula at 15, 25, 45, and 60 min of the experiments and collected in plastic tubes containing 0.1 ml ofindomethacin solution (1 mg indomethacin dissolved in 1 ml of 0.1 M sodium phosphate buffer, pH 8.0) for determination of iTXB2, the stable metabolite of TXA2. The tubes were centrifuged at 1,500 g and the supernatant was stored at -20°C until assay. iTXB2 levels were determined using previously described RIA methods (27) . The iTXB2 antibody does not significantly cross-react with other prostaglandins (< 0.04%). The interassay variability of the iTXB2 assay is 10%.
Infusion ofpurine and xanthine oxidase. Lungs were perfused for 15 min to establish a stable baseline lung weight and PA perfusion pressure. Purine (2 mM) was then instilled into the reservoir followed 5 min later (20 min oftotal perfusion) by xanthine oxidase. Experiments were performed using two concentrations of xanthine oxidase that were 0.003 or 0.012 U/ml perfusate. The lungs were perfused for an additional 40 min monitoring lung weight and PA pressure.
Infusion of platelets with purine and xanthine oxidase. After a 15-min stabilization period, 40 ml of perfusate was withdrawn from the reservoir and purine (2 mM) was instilled. After an additional 4 min of perfusion, 40 ml of washed platelets (1.20±0.07 X 10'°cells) was added to the reservoir. 1 min later (20 min oftotal lung perfusion), either 0.003 or 0.0 12 units/ml of xanthine oxidase was instilled. The lungs were observed for an additional 40 min.
Infusion of G-6-PD-and cyclooxygenase-inhibited platelets with purine and xanthine oxidase. Protocols using platelets preincubated with dehydroepiandrosterone alone to inhibit G-6-PD or preincubated with dehydroepiandrosterone plus acetylsalicylate to inhibit both G-6-PD and cyclooxygenase enzyme were performed at both the 0.003 and 0.0 12 U/ml dose ofxanthine oxidase. Purine (2 mM) was instilled after 15 min of perfusion followed by treated platelets at 19 min, and xanthine oxidase at 20 min.
Experiments with papavarine infusion. After instillation of purine (2 mM), xanthine oxidase (0.003 or 0.012 units/ml), and dehydroepiandrosterone-treated platelets as described above, papavarine (5 mg boluses) was instilled into the reservoir when PA pressure increased by 2 1 mmHg. Additional boluses of papavarine were instilled if the PA pressure did not return to baseline within 2 min or if the pressure increased by 2 1 mmHg again later in the experiment.
Experiments with SQ 29548 infusion. Protocols using infusions of SQ 29548 were identical to those with the infusion of G-6-PD-inhibited platelets with purine and xanthine oxidase except that SQ 29548 (100 uM) was instilled into the reservoir I min after purine (16 min total perfusion). These experiments were performed with both concentrations of xanthine oxidase (0.003 and 0.012 U/ml of perfusate).
Control experiments. To exclude an effect of platelets on the isolated lung, washed platelets (1.20±0.07 X 1010) without purine or xanthine oxidase were instilled into the reservoir after 19 min of perfusion and lungs were observed for a total duration of 60 min. Additional experiments were performed with the instillation of platelets incubated with dehydroepiandrosterone. Dehydroepiandrosterone (lo0 M) was also added directly to the perfusate without platelets or xanthine oxidase and lungs were observed for effects on weight, lung 758 lavage albumin, and PA pressure. Furthermore, dehydroepiandrosterone (10-6 M) was infused with xanthine oxidase into the perfusate without platelets to determine any combined effects of these agents. In vitro platelet iTXB2 generation assay. Untreated washed platelets and washed platelets incubated with dehydroepiandrosterone were assayed for their ability to synthesize and release iTXB2 after stimulation with calcium ionophore A23187. Washed platelets (1 ml, 2 x 108 platelets) were placed in plastic tubes in a 37°C shaking bath. A23 187
(1 IM) in DMSO was added after a 30-s stabilization period, and 20-Ml samples were removed at 30, 60, 90, 120, 180, and 300 s. Control studies were repeated with the addition ofequal volumes ofthe DMSO vehicle. Samples were placed into plastic tubes containing 100 ,uM dazoxiben, a thromboxane synthetase inhibitor, in polyvinylpyrrolidine (PVP) buffer. Assays were performed on these samples for iTXB2 after 1:10 dilution with PVP buffer.
Similar studies were performed to test the ability of purine and xanthine oxidase in concentrations used in the isolated lung to stimulate enhanced iTXB2 release from dehydroepiandrosterone-treated platelets. Purine (2 mM) and xanthine oxidase (0. 12 U/ml) were substituted for calcium ionophore in control and dehydroepiandrosterone-treated platelets, and samples were removed and assayed for iTXB2 as described above.
Statistics 
Results
Control experiments. Recirculating perfusate was nearly free of cellular elements. After the lungs were flushed with 500 ml of 3% BSA-Krebs-Henseleit solution, perfusate leukocyte counts were reduced to 4.1±2.0 cells/cm3, erythrocytes to 12.1±3.3 cells/cm3, and platelets were undetectable.
Control lungs infused with BSA-Krebs-Henseleit alone maintained stable lung weight and PA pressures during the 60-min experiments, and lung lavage albumin contents were 22.9±8.3 mg/dl after completion of perfusion (Table I ). Additional control studies with the infusion of untreated washed platelets alone, dehydroepiandrosterone alone, or G-6-PD-inhibited platelets alone did not affect any measured variable (Table I) . Experiments with the infusion of dehydroepiandrosterone with xanthine oxidase were similar to those with the infusion of xanthine oxidase alone (Table I) .
Effects ofpurine and xanthine oxidase on isolated lung PA pressure and edema. Infusion of purine and xanthine oxidase (0.003 U/ml) (n = 6) caused increases in lung weight (P < 0.05) (Fig. 1) and lung lavage albumin content (P < 0.05) ( Table I ) without changes in PA pressure (Fig. 1 ) compared with control experiments (P = NS). Infusion of a larger xanthine oxidase dose (0.012 U/ml) (n = 10) caused a greater increase in lung weight gain (Fig. 1 ) and lung lavage albumin content ( Table II) that was associated with a rise in PA pressure ( Fig. 1) above control values (P < 0.05).
Effects ofwashed platelets on purine and xanthine oxidaseinduced lung changes. Washed human platelets infused with purine and xanthine oxidase (0.003 U/ml) attenuated the oxidant-induced increases in lung weight (P < 0.05) ( Fig. 1 ) and lung lavage albumin content (P < 0.05) ( Table I ) to levels that were similar to control values. Platelet infusion with the 0.003 U/ml dose of xanthine oxidase did not alter PA pressure from baseline values (Fig. 1) .
Platelets infused with the higher dose of xanthine oxidase (0.012 U/ml) decreased (P < 0.05) but did not completely eliminate the oxidant-induced rise in lung weight gain (Fig. 1) , lung lavage albumin content (Table II) , and PA perfusion pressure (Fig. 1) .
Effects of G-6-PD-inhibited platelets on purine and xanthine oxidase-induced lung changes. Incubation of platelets with dehydroepiandrosterone significantly decreased (P < 0.05) mean platelet G-6-PD activity to 36% ofcontrol platelet values but had only a slight depressive effect on platelet glutathione concentrations (P < 0.05) (Table III) . G-6-PD-inhibited platelets no longer attenuated the increases in lung weight or lung lavage albumin concentration ( Table I ) that occurred after infusion of 0.003 U/ml xanthine oxidase, but rather caused a marked PA pressor response ( Fig. 1 ) and augmention of weight gain (n = 7) (Fig. 1 ) compared with the infusion of purine and xanthine oxidase without platelets (P < 0.05). Infusion of G-6-PD-inhibited platelets caused a similar augmentation of PA pressure, lung weight gain (Fig. 1) , and lung lavage albumin concentration (Table II) when infused with the 0.0 12 units/ml dose of xanthine oxidase (n = 6).
Effects ofpapavarine on lung changes induced by infusion of purine, xanthine oxidase, and G-6-PD-inhibited platelets. Instillation of papavarine (range, 5-20 mg; mean, 12.5 mg) in experiments infused with purine, xanthine oxidase, and G-6-PD-inhibited platelets prevented any rise in PA pressure at both xanthine oxidase concentrations of 0.003 U/ml (n = 6) ( Fig. 2) and 0.012 U/ml (n = 6) (Fig. 2) . Lung weights increased to levels similar to experiments infused with purine and both doses of xanthine oxidase alone, but papavarine prevented the augmentation of lung weight gain observed with G-6-PD-inhibited platelets (Fig. 2) . Lung lavage albumin content was increased after infusion ofpapavarine with both doses of xanthine oxidase confirming the presence of lung edema (Tables I and II) . Effects ofcoincubation ofplatelets with acetylsalicylate and dehydroepiandrosterone before infusion with purine and xanthine oxidase. Platelets incubated with acetylsalicylate and dehydroepiandrosterone to inhibit both platelet cyclooxygenase and G-6-PD were infused with purine and xanthine oxidase. Infusion of treated platelets with the 0.003 U/ml concentration of xanthine oxidase (n = 6) did not result in the augmentation of lung edema or the pressor response observed with the infusion of G-6-PD-inhibited platelets and xanthine oxidase. Lung weight gain (Fig. 3) , lung lavage albumin concentration (Table I) , and PA pressure (Fig. 3) were similar compared to control experiments (P = NS).
Infusion of G-6-PD-and cyclooxygenase-inhibited platelets with the 0.012 U/ml concentration of xanthine oxidase also did not result in augmentation of lung edema or the pressor response. Values for lung weight gain (Fig. 3) and lung lavage albumin content (Table II) were similar to the infusion ofpurine and xanthine oxidase (0.012 U/ml) without platelets, although the PA pressure response remained stable similar to control experiments (Fig. 3) . +.
Effects of coinfusion of SQ 29548 with purine, xanthine oxidase, and G-6-PD-inhibitedplatelets. Instillation of 100,uM SQ 29548 with purine, xanthine oxidase and G-6-PD-inhib- ited platelets prevented the augmented lung edema and pressor response noted with xanthine oxidase and G-6-PD-inhibited platelets. Experiments with the 0.003 U/ml dose of xanthine oxidase (n = 5) demonstrated minimal weight gain not significantly different thqn'control ( Fig. 4 ) and no increase in lung lavage albumin (Table I) or PA pressure (Fig. 4) . Experiments with the 0.012 U/Aml dose of xanthine oxidase (n = 6) demonstrated increases in lung weight (Fig. 4) and lung lavage albumin content (Table IT) similar to the infusion of purine and xanthine oxidase without platelets, but no increases in PA pressure compared with control (Fig. 4) . Perfusate levels of iTXB2. Perfusate samples in all experimental groups were assayed for iTXB2. All samples were below the minimal detectable level (70 pg/ml) for the assay (data not shown).
In vitro platelet generation ofiTXB2. Control platelets and platelets treated with dehydroepiandrosterone were assayed in vitro for TXB2 generation after stimulation by calcium ionophore A 23187 (n = 3). There were no differences between groups in rate or degree of iTXB2 production after stimulation with ionophore (Fig. 5) . Unstimulated platelets had stable basal levels of iTXB2 generation.
Control or dehydroepiandrosterone-treated platelets did not release detectable iTXB2 after incubation with purine and 
Discussion
This study indicates that normal platelets attenuate oxidantinduced lung edema and pulmonary hypertension and that this effect is mediated through platelet G-6-PD activity. Furthermore, the study demonstrates that G-6-PD-inhibited platelets augment oxidant-induced lung edema through platelet cyclooxygenase-dependent hydrostatic mechanisms. The ex vivo model allows detailed examination of the contribution of platelets to measured variables because the lung perfusate does not contain other nonplatelet cellular elements. Additionally, various enzyme inhibiting agents can be incubated with platelets in vivo and removed by washing before instillation of the platelets into the isolated lung system thereby avoiding concurrent inhibition of lung enzyme activity. These studies complement and extend our previous investigations that identified the importance ofthe platelet glutathione redox cycle in the mechanisms of platelet attenuation of oxidant lung injury (19) . Platelets did not prevent xanthine oxidase-induced lung injury if they were incubated with agents that either conjugated reduced glutathione, inhibited glutathione reductase, or prevented glutathione synthesis before infusion into the isolated rabbit lung. Inhibition ofplatelet catalase, however, did not significantly interfere with platelet protective mechanisms (19) .
The present investigation used dehydroepiandrosterone as a specific inhibitor of G-6-PD (20, 21), a necessary enzyme for the generation of NADPH that is required for the reduction of oxidized glutathione by glutathione reductase (22, 23) . Because complete extinction of platelet glutathione regeneration results in cytoskeletal cross-linking and cellular dysfunction (28) , platelet G-6-PD activity was inhibited to only 36% of control values so as to allow sufficient enzyme activity to maintain normal glutathione content and platelet function during basal conditions. This degree ofenzyme inhibition simulates the clinical disorder of G-6-PD deficiency wherein af- fected erythrocytes function normally, except when oxidants overwhelm the regenerative capacity for reduced glutathione leading to hemolysis (29) . Likewise, dehydroepiandrosteronetreated platelets in our study had a normal response to calcium ionophore but an inadequate protective effect against lung edema during xanthine oxidase-induced oxidant stress. The observed absence of platelet attenuation of oxidant lung injury by G-6-PD-inhibited platelets is further evidence of the importance of the platelet glutathione redox cycle in protective mechanisms. These ex vivo studies combined with the in vitro observation that platelets have an avid capacity to reduce extracellular H202 (30) suggest that platelets can metabolize hydroperoxides in the pulmonary circulation, thereby limiting oxidant-induced membrane injury and resultant increased membrane permeability.
These investigations further characterize the contribution of altered hydrostatic pressure on platelet attenuation of lung edema. Infusion of the 0.012 U/ml dose of xanthine oxidase into isolated lungs, as previously reported (19) , caused a rise in PA pressure in addition to increased lung weight and lung lavage albumin content; coinfusion ofwashed human platelets decreased both lung edema and the PA pressure rise, suggesting the possibility that one mechanism whereby platelets attenuated edema was through a reduction in capillary hydrostatic forces. Additional studies were performed using the 0.003 U/ml dose of xanthine oxidase that caused a less severe increase in lung weight and lung lavage albumin content that was associated with PA perfusion pressures similar to control values. Washed platelets prevented increased lung weight and lung lavage albumin content without affecting PA pressure, thereby demonstrating that antioxidant-intact platelets directly limit membrane permeability separate from their capacity to attenuate pulmonary vasoconstriction in this model. more rapidly and to a greater degree in the presence of G-6-PD-inhibited platelets after infusion of either dose of xanthine oxidase (0.003 and 0.0 12 U/ml). G-6-PD-inhibited platelets augmented the PA pressor response induced by the 0.012 U/ml dose of xanthine oxidase and generated a pressor response to the 0.003 U/ml dose of xanthine oxidase, even though this concentration ofenzyme did not cause pulmonary hypertension when infused in the absence of platelets. To investigate whether G-6-PD-inhibited platelets directly increased membrane permeability or augmented lung edema through hydrostatic mechanisms, PA pressures were maintained at control levels by infusing papavarine in experiments with both doses of xanthine oxidase and antioxidant-depleted platelets. Lung edema, as measured by lung weight gain, was similar in these experiments to that observed with the infusion of purine and xanthine oxidase alone without platelets. Thus, G-6-PDinhibited platelets appear to augment oxidant-induced lung edema via vasoconstriction and increased hydrostatic forces that stress the enhanced membrane permeability. Since toxic oxygen metabolites have been demonstrated to aggregate platelets in vitro (31), the vasoconstriction may be mediated through release of platelet vasoactive substances in regions of oxidant stress in the pulmonary microcirculation. We did not observe a direct cytotoxic effect of G-6-PD-inhibited platelets. Platelets release several vasoactive substances that could produce pulmonary hypertension and lung edema by G-6-PD-inhibited platelets ( 13, 14) . The contribution of cyclooxygenase-dependent products, such as endoperoxides or TXA2, was explored because they are potent vasoconstrictors at the postcapillary level (32, 33) . Also, an inverse relationship exists between platelet glutathione content and the capacity ofplatelets to synthesize TXA2 (34, 35) . Inhibition of platelet cyclooxygenase by acetylsalicylate in G-6-PD-inhibited platelets prevented the PA pressor response and augmentation of lung injury observed after the infusion of xanthine oxidase and G-6-PD-inhibited platelets with intact cyclooxygenase enzyme.
Because cyclooxygenase inhibitors interfere with platelet generation of multiple prostaglandins, the specific contribution of endoperoxides and TXA2 using these agents is unclear. Therefore, the effects of the specific competitive TXA2 receptor antagonist, SQ 29548 was evaluated. This compound inhibits the receptor activated by TXA2 and prostaglandin endoperoxides on vascular smooth muscle, with only weak inhibition of contractile responses to prostaglandins F2<t and D2 (36) . Infusion of SQ 29548 prevented the marked pressor response observed with G-6-PD-inhibited platelets at both doses of xanthine oxidase, supporting a role for either endoperoxides or TXA2 in the hydrostatic augmentation of lung edema by G-6-PD-inhibited platelets. Infusion of SQ 29548 in contrast to incubation of G-6-PD-inhibited platelets with acetylsalicylate maintained PA pressures near control values after infusion of xanthine oxidase (Fig. 3) . This observation is interpreted in consideration of previous findings that isolated lungs infused with xanthine oxidase develop TXA2-induced pulmonary hypertension and the source of TXA2 is resident lung cells (37) . Instillation of SQ 29548 into the reservoir would inhibit the effects of the endogenous TXA2 production; incubation of platelets with acetylsalicylate before washing and infusion into the isolated lung would inhibit only the platelet component of eicosanoid release.
A role for TXA2 could not be confirmed by assay of lung perfusate for TXB2 since these samples did not contain measureable levels of iTXB2. These findings are in contrast to previous investigations in isolated rabbit lungs where infusion of xanthine oxidase alone caused lung edema and pulmonary hypertension accompanied by a fivefold increase in perfusate TXB2 levels compared to baseline values (37) . These previous studies, however, used larger doses of xanthine oxidase (0.3 U/ml). The smaller doses used in these studies may be associated with a decreased lung release of TXA2 compared with these previous investigations, thus precluding our ability to measure TXB2.
The absence of detectable iTXB2 in perfusate samples does not exclude TXA2 in the pulmonary pressor response induced by G-6-PD-inhibited platelets and xanthine oxidase. The possibility exists that platelets in the pulmonary microcirculation release TXA2 in close proximity to receptor sites, resulting in a sufficient local concentration to promote vasoconstriction. Furthermore, TXB2 is rapidly taken up by tissues after formation (38) so that circulating TXB2 may reflect only a small fraction of TXA2 production.
We attempted to indirectly identify a role for TXA2 by demonstrating its increased synthesis by G-6-PD-inhibited platelets. In contrast to previous investigations that demonstrated enhanced release of TXA2 from glutathione-deficient platelets (34, 35) , platelets treated with dehydroepiandrosterone did not have augmented synthesis of TXA2 as measured by iTXB2 production. We additionally did not demonstrate that dehydroepiandrosterone-treated platelets generated iTXB2 after stimulation with purine and xanthine oxidase in concentrations instilled in the isolated lung studies. Although previous investigators demonstrated platelet aggregation and release of serotonin after incubation with xanthine and xanthine oxidase (31), a lower concentration of xanthine oxidase was used in the present studies.
This ex vivo investigation may assist in interpreting previous conflicting whole animal studies demonstrating that platelets can either maintain normal pulmonary membrane permeability (39) , augment lung injury (12) , have no effect on membrane permeability (40) , or generate pulmonary hypertension in models of acute lung injury (15, 41) . In models of injury that generate oxidant stress, the antioxidant capacity of the platelets may determine whether they neutralize toxic oxygen metabolites before membrane injury occurs or whether they participate in pathogenetic events by releasing vasoactive substances that augment underlying membrane permeability defects. Considering that platelets have additional potential mechanisms for participation in oxidative processes, such as release of adenine nucleotides that enhance neutrophil release of superoxide anion (42) , the platelet may play an important role in regulating the degree of oxidant-induced lung injury.
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